Entrada Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Collaboration revenue | $129,013 | $— |
| Operating expenses: | ||
| Research and development | 99,884 | 66,609 |
| General and administrative | 32,291 | 30,639 |
| Total operating expenses | 132,175 | 97,248 |
| Loss from operations | (3,162) | (97,248) |
| Other income: | ||
| Interest and other income | 15,218 | 2,632 |
| Total other income | 15,218 | 2,632 |
| Income (loss) before income taxes | 12,056 | (94,616) |
| Income tax | (18,741) | — |
| Net loss | $(6,685) | $(94,616) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.20) | $(3.02) |
| Weighted‑average common shares outstanding, basic and diluted | 33,050,319 | 31,293,312 |
| Other comprehensive loss: | ||
| Unrealized income (loss) on marketable securities, net of tax of $0 | 2,252 | (2,057) |
| Total other comprehensive income (loss) | 2,252 | (2,057) |
| Total comprehensive loss | $(4,433) | $(96,673) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.